EyeCure

EyeCure, located in Wuxi Technology Entrepreneurship Park on the shores of Lake Taihu, is a key technology-leading talent entrepreneurial project introduced by the Wuxi municipal government. The company is committed to building a research and development platform for cell and gene therapy technologies and developing first-class new ophthalmic cell drugs for the treatment of blinding diseases. As a modern biotechnology pharmaceutical enterprise, EyeCure has gathered a group of industry professionals engaged in R&D and clinical studies related to cell and gene therapies and owns several key invention patents. Adhering to the mission of "serving society and benefiting humanity," the company persists in technological innovation, surpassing itself, igniting entrepreneurial passion, and fulfilling entrepreneurial dreams!EyeCure has formed a team specializing in technical R&D, production, and clinical medical transformation for treating ophthalmic diseases, composed of outstanding scientists and technical elites in the field of cell therapy. Guided by its core values of "integrity, openness, and transcendence," the company strictly adheres to scientific norms and explores the profound mysteries of life sciences. After years of accumulation and refinement, EyeCure has established cell laboratories, GMP workshops, and a human-derived RPE cell bank. Utilizing advanced scientific technologies and collaborating with medical platforms, the company facilitates the clinical application of human-derived RPE cells in treating age-related macular degeneration and other diseases. By building a research and development platform for ophthalmic cell and gene therapies, EyeCure accelerates the industrialization of clinical medical research in China and serves as a beacon of hope for restoring human vision.